#1 Clinical Trials Search in Europe

Clinically isolated syndrome – Treatment

Go back

Clinically isolated syndrome represents a pivotal moment in neurology—a first neurological episode that may signal the beginning of multiple sclerosis or remain a single, isolated event, leaving patients and doctors navigating uncertainty about what lies ahead.

Understanding Treatment Goals and Approaches

When a person experiences clinically isolated syndrome for the first time, the central goal of treatment revolves around managing immediate symptoms, slowing the potential progression toward multiple sclerosis, and improving long-term quality of life. Treatment decisions depend heavily on whether brain scans show lesions similar to those seen in MS, the severity of symptoms, and individual patient characteristics like age and overall health.[1]

Not everyone with clinically isolated syndrome will need the same level of medical intervention. The approach varies significantly between those considered at high risk of developing MS—typically individuals whose magnetic resonance imaging (a brain scanning technology known as MRI) reveals multiple areas of damage—and those at lower risk who may have experienced a single episode without visible brain lesions. For patients whose scans show several lesions, early treatment becomes particularly important because it may delay or prevent a second neurological episode, which would confirm an MS diagnosis.[3]

Medical societies and expert panels have developed standard treatments that are approved and widely used, but researchers continue investigating new therapies through clinical trials. These ongoing studies aim to find better ways to protect the nervous system from damage and to understand which patients will benefit most from early intervention. The treatment landscape includes both established medications originally designed for multiple sclerosis and experimental approaches being tested specifically for people with clinically isolated syndrome.[2]

⚠️ Important
Being diagnosed with clinically isolated syndrome does not automatically mean you will develop multiple sclerosis. Studies show that when MRI scans reveal brain lesions similar to those seen in MS, the risk of later developing MS ranges from 60 to 80 percent. However, if no lesions appear on the scan, the risk drops to approximately 20 percent. Your neurologist will carefully evaluate your individual situation before recommending any treatment course.[3]

Standard Treatment Approaches

The standard treatment for clinically isolated syndrome borrows heavily from therapies approved for multiple sclerosis, particularly when patients are classified as high risk. Currently, there is no cure for clinically isolated syndrome, but several medications have been approved by the Food and Drug Administration to manage symptoms and potentially delay the onset of MS. These medications fall under the category of disease-modifying drugs, which are treatments designed to reduce the frequency and severity of neurological episodes by affecting how the immune system behaves.[1]

Disease-modifying drugs work by dampening the inflammatory response that causes damage to myelin, the protective fatty coating surrounding nerve cells in the brain and spinal cord. When the immune system mistakenly attacks myelin—a process called demyelination—nerve signals become disrupted, leading to the various symptoms people experience with clinically isolated syndrome. By reducing this inflammation, disease-modifying drugs aim to prevent further damage and preserve neurological function over time.[3]

Clinical guidelines from international expert panels, including the McDonald diagnostic criteria, now incorporate MRI evidence showing damage spread across different areas of the nervous system and occurring at different times. This allows doctors to make more informed decisions about when to start treatment. When brain scans reveal multiple lesions that match the pattern seen in multiple sclerosis, many neurologists recommend beginning disease-modifying therapy even after just one clinical episode. This early intervention strategy is based on research showing that treatment can prolong the time before a second episode occurs and may reduce long-term disability.[2]

The duration of therapy varies from person to person and depends on how the condition evolves. Some patients may take disease-modifying drugs for many years, while others might stop if they remain stable without additional episodes. Doctors typically schedule routine checkups to monitor for signs of disease progression through repeated MRI scans and neurological examinations. These follow-up visits help determine whether the treatment is working or if adjustments are needed.[1]

Like all medications, disease-modifying drugs can cause side effects. The specific side effects depend on which medication is prescribed, but patients should discuss potential risks with their medical team. Some medications are given by injection, others are taken as pills, and some require intravenous infusion in a medical facility. Choosing the right medication involves carefully weighing the potential benefits against the risks and considering factors like how often the medication needs to be taken and what side effects the patient can tolerate. Close collaboration with an experienced neurologist or MS specialist is essential for making these decisions.[1]

Experimental Treatments in Clinical Trials

Beyond standard approved therapies, researchers are actively investigating new treatment options for people with clinically isolated syndrome through clinical trials. These studies test promising drugs and therapeutic approaches that may one day become part of routine care. Clinical trials follow a structured process, progressing through different phases that each answer specific questions about a new treatment.

Phase I trials primarily focus on safety, testing a new drug or therapy in a small group of people to determine what dose is safe and to identify potential side effects. Phase II trials expand to a larger group and begin evaluating whether the treatment actually works—does it reduce symptoms, prevent new brain lesions, or delay disease progression? Phase III trials involve even more participants and compare the new treatment directly against current standard therapies or placebo to confirm its effectiveness and monitor for side effects across a broader population.[8]

One major area of research involves immunotherapy, which includes various approaches to modulating the immune system’s behavior. Since clinically isolated syndrome and multiple sclerosis involve the immune system attacking the nervous system, researchers are developing more precise ways to calm this immune response without suppressing the body’s ability to fight infections. Different types of immunotherapy work through different mechanisms—some block specific immune cells from entering the brain and spinal cord, others interfere with inflammatory signaling molecules, and still others attempt to “retrain” the immune system to tolerate myelin.[8]

Clinical trials for people with clinically isolated syndrome or early relapsing-remitting multiple sclerosis often investigate whether treatments can prevent disability progression, reduce the frequency of relapses, or improve quality of life. Researchers track various outcomes, including changes on the Expanded Disability Status Scale (a standardized measure of physical disability), the number of new or enlarging lesions visible on MRI scans, and how often patients experience new neurological symptoms. Some trials also examine whether certain demographic characteristics, clinical features, or biomarkers can predict which patients will respond best to specific treatments, moving toward a more personalized medicine approach.[8]

Trial locations vary widely. Some studies take place at specialized research centers in the United States, while others are conducted across Europe or involve international collaboration. Patient eligibility depends on specific criteria set by each study, which typically include factors like age, how recently the first neurological episode occurred, what MRI findings are present, and whether the person has had more than one episode. People interested in participating in clinical trials should discuss options with their neurologist, who can help identify appropriate studies and explain what participation would involve.

Managing Specific Symptoms and Supportive Care

Beyond disease-modifying drugs, many people with clinically isolated syndrome benefit from treatments aimed at managing specific symptoms. Depending on which part of the nervous system was affected during the episode, symptoms can vary widely. Someone who experienced optic neuritis—inflammation of the optic nerve affecting vision—may need different supportive care compared to someone who had spinal cord inflammation causing numbness and weakness in the legs.[1]

Vision problems such as double vision or temporary vision loss may improve on their own over time as inflammation subsides and the body repairs some of the myelin damage. However, some patients receive corticosteroids during the acute phase to speed recovery, though this approach is more common once someone has been diagnosed with definite MS rather than clinically isolated syndrome alone. For muscle stiffness or spasticity, physical therapy can help maintain flexibility and strength. Bladder or bowel control difficulties may improve with behavioral strategies, pelvic floor exercises, or medications specifically designed to help with urinary urgency or retention.[1]

Fatigue represents one of the most challenging symptoms for many people. Even though it may not be visible to others, profound tiredness can significantly impact daily activities, work, and social life. Managing fatigue often requires a multifaceted approach including regular exercise tailored to individual abilities, good sleep habits, and sometimes medications. Psychological support also plays an important role, as receiving a diagnosis of clinically isolated syndrome can trigger anxiety about the future, particularly the uncertainty about whether MS will develop. Counseling, support groups, or connecting with others who have experienced similar situations can provide valuable emotional support.[3]

Rehabilitation services, including physical therapy, occupational therapy, and speech therapy, may be recommended depending on which symptoms are present. These therapies focus on maintaining function, developing strategies to work around limitations, and preventing complications. For example, someone experiencing coordination difficulties might benefit from occupational therapy to learn safer ways to perform daily tasks, while someone with weakness might work with a physical therapist to build strength and prevent falls.

Most Common Treatment Methods

  • Disease-Modifying Drugs
    • FDA-approved medications originally designed for multiple sclerosis that may be prescribed for high-risk clinically isolated syndrome patients
    • These medications work by reducing inflammation and preventing immune system attacks on myelin
    • Treatment aims to reduce the frequency and severity of neurological episodes
    • Medications can be administered by injection, oral tablets, or intravenous infusion
    • Choosing the right medication involves careful consideration of risks and benefits with an experienced medical team[1]
  • Immunotherapy
    • Various approaches tested in clinical trials that modulate immune system behavior
    • Different mechanisms include blocking immune cells from entering the central nervous system, interfering with inflammatory signals, or retraining immune tolerance
    • Trials investigate whether treatments can prevent disability progression and reduce relapse frequency
    • Research focuses on demographic, clinical, and biomarker subgroups to enable personalized treatment approaches[8]
  • Symptom Management
    • Physical therapy for muscle stiffness, spasticity, and coordination difficulties
    • Occupational therapy to develop strategies for daily activities and prevent complications
    • Behavioral strategies and medications for bladder or bowel control issues
    • Fatigue management through exercise programs, sleep hygiene, and sometimes medications
    • Psychological counseling and support groups for emotional well-being[1][3]
  • Regular Monitoring
    • Routine checkups with neurological examinations to detect any progression toward MS
    • Repeated MRI scans to monitor for new or enlarging brain lesions
    • Assessment using standardized disability scales to track functional changes over time
    • Lumbar puncture and cerebrospinal fluid analysis may be performed to look for oligoclonal bands, which are associated with higher MS risk[1][2]

Ongoing Clinical Trials on Clinically isolated syndrome

  • Study on B-Cell Levels in Infants Exposed to Ocrelizumab During Pregnancy for Mothers with Multiple Sclerosis or Clinically Isolated Syndrome

    Not recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Germany Spain

References

https://www.cedars-sinai.org/health-library/diseases-and-conditions/c/clinically-isolated-syndrome.html

https://pmc.ncbi.nlm.nih.gov/articles/PMC5353226/

https://mstrust.org.uk/a-z/clinically-isolated-syndrome-cis

https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-022-01997-2

More information about
Clinically isolated syndrome:

FAQ

Will I definitely get multiple sclerosis if I’ve been diagnosed with clinically isolated syndrome?

Not necessarily. The likelihood depends largely on MRI findings. If brain scans show multiple lesions similar to those seen in MS, there’s a 60 to 80 percent chance of developing MS within several years. However, if no lesions are visible, the risk drops to about 20 percent. Some people experience only one episode and never have further symptoms.[3]

What symptoms might I experience with clinically isolated syndrome?

Symptoms vary depending on which part of the central nervous system is affected. Common symptoms include numbness or tingling, vision problems like double vision, muscle weakness or stiffness, difficulty with walking and coordination, bladder or bowel control issues, dizziness, and fatigue. You might experience just one symptom (monofocal episode) or several at once (multifocal episode).[1]

How do doctors diagnose clinically isolated syndrome?

Diagnosis begins with a detailed medical history and neurological examination. Because CIS can mimic other nervous system disorders, diagnostic tests help rule out other causes. These typically include MRI scans of the brain and spinal cord, and may involve a lumbar puncture (spinal tap) with cerebrospinal fluid analysis, nerve function tests, and blood tests. No single test confirms CIS—diagnosis requires combining clinical findings with test results.[1]

Should I start treatment immediately after being diagnosed with clinically isolated syndrome?

Treatment decisions depend on your individual risk level. If you’re considered high risk—typically because MRI scans show brain lesions consistent with MS—early treatment with disease-modifying drugs may delay the onset of MS and reduce long-term disability. However, if you’re at lower risk, your doctor may recommend a watch-and-wait approach with regular monitoring. The decision should be made collaboratively with your neurologist after carefully weighing risks and benefits.[3]

Are clinical trials available for people with clinically isolated syndrome?

Yes, researchers are actively conducting clinical trials investigating new treatments for clinically isolated syndrome and early multiple sclerosis. These studies test immunotherapies and other approaches in different phases, from safety testing to comparing new treatments with standard therapies. Trial locations vary across the United States, Europe, and internationally. Eligibility depends on specific criteria including age, timing of symptoms, and MRI findings. Discuss clinical trial options with your neurologist.[8]

🎯 Key Takeaways

  • • Clinically isolated syndrome represents a first neurological episode lasting at least 24 hours that may or may not progress to multiple sclerosis—the outcome varies significantly between individuals.
  • • MRI brain scans showing lesions similar to MS patterns dramatically increase the likelihood of later developing MS, from 20 percent with no lesions to 60-80 percent with multiple lesions.
  • • Early treatment with disease-modifying drugs in high-risk patients may delay MS onset and reduce long-term disability, though there’s no cure for clinically isolated syndrome.
  • • Symptoms vary widely depending on which nervous system area is affected, ranging from vision problems to muscle weakness, numbness, coordination difficulties, or bladder issues.
  • • In 85 percent of young adults who eventually develop MS, the disease starts with an acute episode of clinically isolated syndrome affecting optic nerves, brainstem, or spinal cord.
  • • Clinical trials are actively testing new immunotherapies and personalized treatment approaches, offering additional options beyond standard approved medications.
  • • Regular monitoring through neurological exams and repeat MRI scans helps determine if the condition is progressing and whether treatment adjustments are needed.
  • • Beyond disease-modifying drugs, symptom management through physical therapy, psychological support, and rehabilitation services plays a crucial role in maintaining quality of life.

Connected medications: